Summit Therapeutics SMMT Net Income
Net Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's net income?
- Summit Therapeutics (SMMT) reported net income of -$189.42M in Q1 2026.
- How has Summit Therapeutics's net income changed year-over-year?
- Summit Therapeutics's net income decreased by 201.1% year-over-year, from -$62.91M to -$189.42M.
- What is the long-term trend for Summit Therapeutics's net income?
- Over 4 years (2021 to 2025), Summit Therapeutics's net income has grown at a 86.8% compound annual growth rate (CAGR), from -$88.6M to -$1.08B.
- What does net income mean?
- The total profit or loss generated by the company during the period.
- How do you interpret net income?
- An increase indicates improved profitability, while a decrease or larger loss signals potential operational challenges or high investment costs.
- How does net income compare across companies?
- Standard across all public companies; biopharma firms often show negative net income during heavy R&D phases.